Microparticle Reagent Multiplexed SARS-CoV-2 Antigen Antibody Detection

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

There is a need for effective methods to assess the presence and quantity of SARS-CoV-2 antigens and antibodies in biological samples, particularly for rapid and accurate diagnosis and monitoring of COVID-19 infections.

Innovation Solution

A method involving microparticle reagents that specifically bind to SARS-CoV-2 antigens and antibodies, with detectable labels forming complexes to indicate the presence or amount of these components in biological samples, allowing for simultaneous or sequential detection in a biological sample.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Loss of time

If conventional separate detection methods are used for SARS-CoV-2 antigens and antibodies, then detection accuracy is maintained, but detection time and procedural complexity increase

Engineering Contradiction:
Improvedetection timeVSAvoidprocedural complexity
Core Design Contradiction:
Loss of timeVSDevice complexity

Solution Approach 1:

The patent combines separate antigen and antibody detection into a single multiplexed assay using microparticle-based flow cytometry. Multiple detection targets are simultaneously analyzed in one test, eliminating the need for sequential separate tests and reducing overall detection time while maintaining accuracy.

Inventive Principle:
Principle #5Merging (Combining)

Solution Approach 2:

The microparticle flow cytometry platform serves multiple detection functions simultaneously - detecting both SARS-CoV-2 antigens and antibodies, as well as other parameters, within a single universal system. This multi-functional approach reduces procedural complexity compared to using separate specialized tests.

Inventive Principle:
Principle #6Universality (Multi-functionality)

2Speed

If rapid detection methods are implemented for SARS-CoV-2, then detection speed increases, but measurement precision may deteriorate

Engineering Contradiction:
Improvedetection speedVSAvoidquantification accuracy
Core Design Contradiction:
SpeedVSMeasurement precision

Solution Approach 1:

The patent replaces traditional mechanical/chemical assay methods with flow cytometry detection, which uses optical scattering and fluorescence detection. This substitution enables rapid automated analysis with high precision quantification, achieving both fast detection speeds and accurate measurement through optical physics rather than mechanical processes.

Inventive Principle:
Principle #28Mechanics substitution (Replace mechanical system)

Solution Approach 2:

The use of microparticles with detectable labels creates optical copies or signals that represent the presence and quantity of target antigens and antibodies. These optical signals can be rapidly detected and quantified with high precision, maintaining measurement accuracy while enabling fast throughput.

Inventive Principle:
Principle #26Copying

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

Enables rapid and accurate detection of SARS-CoV-2 antigens and antibodies in biological samples, facilitating timely diagnosis and monitoring of COVID-19 infections, with the potential for point-of-care applications.

Implementation Method 1

microparticle reagents that specifically bind to SARS-CoV-2 antigens and antibodies

Methodology Applied
Scientific EffectAntigen-antibody binding:

Implementation Method 2

detectable labels forming complexes to indicate the presence or amount of these components

Methodology Applied
Scientific EffectDetectable label signal generation:

Data Source

PatentUS20240069037A1Methods for determining SARS-cov-2 antigen and Anti-SARS-cov-2 antibody in a sample
Publication Date: 2024.02.29 ABBOTT LAB INC

AI summary

Disclosed herein are methods, kits, and systems for detecting at least one type of SARS-CoV-2 antigen and at least one type of anti-SARS-CoV-2 antibody in a subject, which comprises the use of at least two different types of microparticle reagents for binding at least one type of SARS-CoV-2 antigen and at least one type of anti-SARS-CoV-2 antibody and at least two different types of detection reagents for binding each of the microparticle reagents.